Aditya Bardia

Program Director, Breast Medical Oncology & Assistant Chief, Translational Research, Division of Hematology-Oncology UCLA

Dr. Aditya Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly antibody drug conjugates. He is the principal investigator of several clinical trials investigating precision therapeutics, and he has led the clinical development of novel therapies, including sacituzumab govitecan (IMMU-132), the first ADC approved for patients with metastatic TNBC, elacestrant, the first oral SERD approved for patients with metastatic HR+ breast cancer. Dr. Bardia led the clinical development of blood-based biomarkers, such as CTCs and ctDNA, as “liquid biopsy” for identification of novel targets, therapy selection, monitoring, and understanding resistance to guide therapeutic development.

Seminars

Tuesday 4th November 2025
Reviewing the ADC Clinical & Approval Landscape: What Direction are ADCs Heading to Reshape Frontline Oncology Treatments For Patients?
8:00 am
  • Reviewing the breast cancer patient treatment landscape: Where do ADCs currently fit in with standard of care treatments and how is this evolving?
  • Explaining the physician’s perspective and patient attitudes to ADC treatments given anti-tumor efficacy and toxicity profiles
  • Assessing the rise of ADC patient resistance mechanisms and explaining the importance of mechanism and design differentiation to provide long-term patient benefit
Aditya Bardia - 16th World ADC San Diego